Risk factors for elevated intraocular pressure after trans-tenon retrobulbar injections of triamcinolone

Kazuyuki Hirooka, Fumio Shiraga, Shigeto Tanaka, Tetsuya Baba, Hiroshi Mandai

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: To determine the risk factors that induce an elevation of intraocular pressure (IOP) after trans-Tenon retrobulbar injections of triamcinolone acetonide. Methods: We retrospectively reviewed the medical records of 49 consecutive patients (49 eyes) with choroidal neovascularization or diffuse diabetic macular edema who had received one trans-Tenon retrobulbar injection of triamcinolone acetonide (20 mg) between June 2003 and September 2004, while being treated at Kagawa University Hospital or Okayama Saiseikai General Hospital. Diabetes mellitus had been diagnosed in ten of the patients. Steroid responders were defined as having a relative increase in intraocular pressure (IOP) of >6 mmHg and an absolute IOP >20 mmHg with an anatomically open anterior chamber angle. The mean follow-up time was 4.2 ± 0.2 months (range, 3-6 months). Results: Nine patients were responders and 40 patients were nonresponders. The elevation of the IOP occurred 1 to 4 weeks after the injection. The only preoperative predictive factor for the steroid responders was the presence of diabetes mellitus (multiple logistic regression analysis, odds ratio = 32.78, P = 0.006). After topical glaucoma medication, the IOP returned to acceptable levels in all responders. Conclusions: Our results suggest an association between diabetes mellitus and elevated IOP after a trans-Tenon retrobulbar triamcinolone acetonide injection.

Original languageEnglish
Pages (from-to)235-238
Number of pages4
JournalJapanese Journal of Ophthalmology
Volume50
Issue number3
DOIs
Publication statusPublished - May 2006
Externally publishedYes

Fingerprint

Triamcinolone
Intraocular Pressure
Triamcinolone Acetonide
Injections
Diabetes Mellitus
Steroids
Choroidal Neovascularization
Macular Edema
Anterior Chamber
General Hospitals
Glaucoma
Medical Records
Logistic Models
Odds Ratio
Regression Analysis

Keywords

  • Diabetes mellitus
  • Intraocular pressure
  • Risk factor
  • Steroid responder
  • Triamcinolone acetonide

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Risk factors for elevated intraocular pressure after trans-tenon retrobulbar injections of triamcinolone. / Hirooka, Kazuyuki; Shiraga, Fumio; Tanaka, Shigeto; Baba, Tetsuya; Mandai, Hiroshi.

In: Japanese Journal of Ophthalmology, Vol. 50, No. 3, 05.2006, p. 235-238.

Research output: Contribution to journalArticle

Hirooka, Kazuyuki ; Shiraga, Fumio ; Tanaka, Shigeto ; Baba, Tetsuya ; Mandai, Hiroshi. / Risk factors for elevated intraocular pressure after trans-tenon retrobulbar injections of triamcinolone. In: Japanese Journal of Ophthalmology. 2006 ; Vol. 50, No. 3. pp. 235-238.
@article{4f5259325f1447b4befd85d532bb7354,
title = "Risk factors for elevated intraocular pressure after trans-tenon retrobulbar injections of triamcinolone",
abstract = "Purpose: To determine the risk factors that induce an elevation of intraocular pressure (IOP) after trans-Tenon retrobulbar injections of triamcinolone acetonide. Methods: We retrospectively reviewed the medical records of 49 consecutive patients (49 eyes) with choroidal neovascularization or diffuse diabetic macular edema who had received one trans-Tenon retrobulbar injection of triamcinolone acetonide (20 mg) between June 2003 and September 2004, while being treated at Kagawa University Hospital or Okayama Saiseikai General Hospital. Diabetes mellitus had been diagnosed in ten of the patients. Steroid responders were defined as having a relative increase in intraocular pressure (IOP) of >6 mmHg and an absolute IOP >20 mmHg with an anatomically open anterior chamber angle. The mean follow-up time was 4.2 ± 0.2 months (range, 3-6 months). Results: Nine patients were responders and 40 patients were nonresponders. The elevation of the IOP occurred 1 to 4 weeks after the injection. The only preoperative predictive factor for the steroid responders was the presence of diabetes mellitus (multiple logistic regression analysis, odds ratio = 32.78, P = 0.006). After topical glaucoma medication, the IOP returned to acceptable levels in all responders. Conclusions: Our results suggest an association between diabetes mellitus and elevated IOP after a trans-Tenon retrobulbar triamcinolone acetonide injection.",
keywords = "Diabetes mellitus, Intraocular pressure, Risk factor, Steroid responder, Triamcinolone acetonide",
author = "Kazuyuki Hirooka and Fumio Shiraga and Shigeto Tanaka and Tetsuya Baba and Hiroshi Mandai",
year = "2006",
month = "5",
doi = "10.1007/s10384-005-0306-9",
language = "English",
volume = "50",
pages = "235--238",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Risk factors for elevated intraocular pressure after trans-tenon retrobulbar injections of triamcinolone

AU - Hirooka, Kazuyuki

AU - Shiraga, Fumio

AU - Tanaka, Shigeto

AU - Baba, Tetsuya

AU - Mandai, Hiroshi

PY - 2006/5

Y1 - 2006/5

N2 - Purpose: To determine the risk factors that induce an elevation of intraocular pressure (IOP) after trans-Tenon retrobulbar injections of triamcinolone acetonide. Methods: We retrospectively reviewed the medical records of 49 consecutive patients (49 eyes) with choroidal neovascularization or diffuse diabetic macular edema who had received one trans-Tenon retrobulbar injection of triamcinolone acetonide (20 mg) between June 2003 and September 2004, while being treated at Kagawa University Hospital or Okayama Saiseikai General Hospital. Diabetes mellitus had been diagnosed in ten of the patients. Steroid responders were defined as having a relative increase in intraocular pressure (IOP) of >6 mmHg and an absolute IOP >20 mmHg with an anatomically open anterior chamber angle. The mean follow-up time was 4.2 ± 0.2 months (range, 3-6 months). Results: Nine patients were responders and 40 patients were nonresponders. The elevation of the IOP occurred 1 to 4 weeks after the injection. The only preoperative predictive factor for the steroid responders was the presence of diabetes mellitus (multiple logistic regression analysis, odds ratio = 32.78, P = 0.006). After topical glaucoma medication, the IOP returned to acceptable levels in all responders. Conclusions: Our results suggest an association between diabetes mellitus and elevated IOP after a trans-Tenon retrobulbar triamcinolone acetonide injection.

AB - Purpose: To determine the risk factors that induce an elevation of intraocular pressure (IOP) after trans-Tenon retrobulbar injections of triamcinolone acetonide. Methods: We retrospectively reviewed the medical records of 49 consecutive patients (49 eyes) with choroidal neovascularization or diffuse diabetic macular edema who had received one trans-Tenon retrobulbar injection of triamcinolone acetonide (20 mg) between June 2003 and September 2004, while being treated at Kagawa University Hospital or Okayama Saiseikai General Hospital. Diabetes mellitus had been diagnosed in ten of the patients. Steroid responders were defined as having a relative increase in intraocular pressure (IOP) of >6 mmHg and an absolute IOP >20 mmHg with an anatomically open anterior chamber angle. The mean follow-up time was 4.2 ± 0.2 months (range, 3-6 months). Results: Nine patients were responders and 40 patients were nonresponders. The elevation of the IOP occurred 1 to 4 weeks after the injection. The only preoperative predictive factor for the steroid responders was the presence of diabetes mellitus (multiple logistic regression analysis, odds ratio = 32.78, P = 0.006). After topical glaucoma medication, the IOP returned to acceptable levels in all responders. Conclusions: Our results suggest an association between diabetes mellitus and elevated IOP after a trans-Tenon retrobulbar triamcinolone acetonide injection.

KW - Diabetes mellitus

KW - Intraocular pressure

KW - Risk factor

KW - Steroid responder

KW - Triamcinolone acetonide

UR - http://www.scopus.com/inward/record.url?scp=33745085565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745085565&partnerID=8YFLogxK

U2 - 10.1007/s10384-005-0306-9

DO - 10.1007/s10384-005-0306-9

M3 - Article

VL - 50

SP - 235

EP - 238

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 3

ER -